Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

CHRNA7 Antikörper (Middle Region)

CHRNA7 Reaktivität: Human WB Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN630113
  • Target Alle CHRNA7 Antikörper anzeigen
    CHRNA7 (Cholinergic Receptor, Nicotinic, alpha 7 (Neuronal) (CHRNA7))
    Bindungsspezifität
    • 15
    • 14
    • 8
    • 5
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Middle Region
    Reaktivität
    • 66
    • 38
    • 34
    • 7
    • 5
    • 4
    • 3
    • 3
    • 3
    • 3
    • 2
    • 1
    Human
    Wirt
    • 56
    • 12
    • 2
    Kaninchen
    Klonalität
    • 56
    • 13
    Polyklonal
    Konjugat
    • 31
    • 5
    • 4
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser CHRNA7 Antikörper ist unkonjugiert
    Applikation
    • 57
    • 25
    • 13
    • 13
    • 13
    • 6
    • 5
    • 4
    • 3
    • 3
    • 3
    • 2
    • 1
    • 1
    Western Blotting (WB)
    Spezifität
    CHRNA7 antibody was raised against the middle region of CHRNA7
    Aufreinigung
    Purified
    Immunogen
    CHRNA7 antibody was raised using the middle region of CHRNA7 corresponding to a region with amino acids VPTPDSGVVCGRMACSPTHDEHLLHGGQPPEGDPDLAKILEEVRYIANRF
    Top Product
    Discover our top product CHRNA7 Primärantikörper
  • Applikationshinweise
    WB: 1.25 µg/mL
    Optimal conditions should be determined by the investigator.
    Kommentare

    CHRNA7 Blocking Peptide, catalog no. 33R-9739, is also available for use as a blocking control in assays to test for specificity of this CHRNA7 antibody

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Lyophilized
    Rekonstitution
    Lyophilized powder. Add distilled water for a 1 mg/mL concentration of CHRNA7 antibody in PBS
    Konzentration
    Lot specific
    Buffer
    PBS
    Handhabung
    Avoid repeated freeze/thaw cycles.
    Dilute only prior to immediate use.
    Lagerung
    4 °C/-20 °C
    Informationen zur Lagerung
    Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
  • Target
    CHRNA7 (Cholinergic Receptor, Nicotinic, alpha 7 (Neuronal) (CHRNA7))
    Andere Bezeichnung
    CHRNA7 (CHRNA7 Produkte)
    Synonyme
    CHRNA7-2 antikoerper, NACHRA7 antikoerper, dZ70B1.1 antikoerper, Acra7 antikoerper, alpha7 antikoerper, BTX antikoerper, NARAD antikoerper, nAChRa7 antikoerper, CHRNA7 antikoerper, cholinergic receptor nicotinic alpha 7 subunit antikoerper, neuronal acetylcholine receptor subunit alpha-7 antikoerper, cholinergic receptor, nicotinic, alpha 7 (neuronal) antikoerper, cholinergic receptor, nicotinic, alpha polypeptide 7 antikoerper, cholinergic receptor, nicotinic, alpha 7 antikoerper, CHRNA7 antikoerper, LOC100374356 antikoerper, chrna7 antikoerper, Chrna7 antikoerper, LOC100060521 antikoerper
    Hintergrund
    The protein encoded by CHRNA7 displays marked permeability to calcium ions and is a major component of brain nicotinic receptors that are blocked by, and highly sensitive to, alpha-bungarotoxin. Once this receptor binds acetylcholine, it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. This gene is located in a region identified as a major susceptibility locus for juvenile myoclonic epilepsy and a chromosomal location involved in the genetic transmission of schizophrenia.
    Molekulargewicht
    56 kDa (MW of target protein)
    Pathways
    Synaptic Membrane
Sie sind hier:
Kundenservice